Brexit Frictions Leave Medicines Supply Chains Exposed
Britain’s medicines shortages are no longer just a domestic supply problem; they are now a cross-border policy failure with direct clinical consequences. The BMJ opinion argues that the United Kingdom is being left behind as the European Union strengthens its response to shortages, with patients already bearing the cost of disrupted access to antibiotics, epilepsy medicines, and other essential products.
Manufacturing shocks linked to covid-19 and the war in Ukraine collided with years of pressure on generic drug prices and profit margins. When supply chains tightened, there was little slack left to absorb interruptions. The result was a fragile market in which even modest production or shipping problems could cascade into national shortages. For prescribers, pharmacists, and patients, the issue is not abstract. A missing formulation can mean treatment delays, therapeutic substitution, and extra work for already strained primary and hospital services.
The article points to a striking overlap between the United Kingdom and France even when comparisons are narrowed to the same dose, ingredient, and formulation. Almost half of products in serious shortage in the UK in 2025 — 41 out of 85 products — had already been notified to French authorities as facing a supply disruption in the previous two years. The overlap is clinically important because it shows that Britain is not dealing with a uniquely British supply crisis in many cases. It is facing a shared continental vulnerability in a market shaped by the same manufacturers, routes, and production constraints.
A shortage in one country can quickly become a shortage everywhere when the same fragile suppliers feed both systems.
Shared Markets, Unequal Access to Solutions
The UK still sits inside the same broader European supply environment, but it no longer has the same access to coordinated policy tools. Brexit has turned moving medicines into Great Britain and back out again into a heavier administrative burden. The piece argues that some of this friction was inevitable once the UK chose a hard Brexit, yet several barriers remain political choices rather than unavoidable consequences.
One of the clearest examples is batch testing. The EU does not accept batch testing performed in the UK, even though it does recognize testing done in several other non-member countries. Batch testing is the final quality-control step before medicines are released, so duplicate testing creates delay, cost, and an extra layer of bureaucracy. In a stable market that might be manageable. In a market already strained by shortages, it becomes one more obstacle between manufacture and bedside use.
The policy gap matters because medicines shortages are no longer merely reactive problems. The EU is now trying to address them through long-term investment, information sharing, and mechanisms that can protect supply before a crisis becomes visible in pharmacies and wards. The UK is outside those structures. It can still receive information informally, but it is not part of the formalized coordination that would allow both sides to anticipate problems and discuss stock-shifting options in a more systematic way.
EU Shortage Powers Move Ahead Without the UK
The European Union’s Critical Medicine Act gives member states tools that go beyond crisis management. It can subsidize firms, require companies to prioritize EU supply, and allow member states to favor EU suppliers. Those provisions are designed to reduce dependence on complex global supply chains and to prevent one region’s shortage from spreading unchecked. They also make clear that the EU is approaching medicines security as an industrial and strategic issue, not simply a pharmacy-level inconvenience.
Britain is not part of that architecture. Instead, it remains a third country competing for the same manufacturing capacity and the same limited shipping and testing bandwidth. In practice, that means the UK can be affected by decisions taken in Brussels even when it has no seat in the room. For a country still responsible for securing medications for millions of patients, that is a hazardous position.
The briefing behind the opinion piece, based on a roundtable sponsored by Medicines UK, makes the point that cooperation is possible but must be carefully structured. The EU will not want arrangements that appear to hand Britain a competitive advantage. That suspicion is rooted in the politics of Brexit and in memories of earlier negotiations. Yet the article also suggests that the scale of current shortages creates an opening for narrower, practical cooperation focused on patient safety rather than symbolism.
Testing, Data, and Inspection as Practical Levers
The most realistic path forward is not a grand constitutional reset but a series of targeted changes. Among the options discussed are alignment on testing and third-country cooperation, both of which would help shorten delays and reduce duplication. The piece also points to digital patient information leaflets and the possibility of UK inspectors taking on a larger share of inspections of overseas factories that both systems recognize.
These are not glamorous reforms. They are administrative fixes. But medicines shortages are often managed or worsened in precisely these administrative seams, where delays, duplicated checks, and gaps in communication can make a fragile supply chain fail. A system built around mutual trust and technical equivalence can function with far less waste than one defined by suspicion and separation.
There is also a strategic argument. If the UK wants the EU to view it as a serious partner in health security, it has to show that cooperation solves problems for both sides. Offering capacity, standards alignment, or shared inspection work could help demonstrate value rather than simply seeking exemptions. That is especially important if the government wants to persuade EU counterparts that cooperation on medicines is about resilience rather than commercial advantage.
Health Security as a Test of Political Credibility
The article lands on a blunt political reality: the biggest barrier is persuading the EU that the change is worth making. That is not a technical challenge alone. It is a trust challenge, and trust has been damaged by years of Brexit negotiations. Even so, the clinical stakes remain immediate. When supply chains fail, pharmacists are forced into substitutions, clinicians may need to alter regimens, and patients can lose confidence in therapies they depend on every day.
For epilepsy treatment, antibiotic access, and hormone-related therapies, inconsistency in supply can alter adherence and complicate care. The problem is not only whether a medicine exists somewhere in the system, but whether the right dose and formulation are available when needed. Those distinctions matter at the bedside, in the dispensary, and across health systems that have little room for avoidable disruption.
The final message is straightforward: medicines security has become part of national resilience, not a niche procurement issue. Britain cannot rely on distance from Europe to insulate it from shortages that are already shared across the continent. Without more direct cooperation on testing, information, and manufacturing oversight, the same vulnerabilities will keep circulating through both markets, with patients left to absorb the consequences.